Articles from Profluent
Profluent Named 2026 Emerging Innovator Of The Year At 23rd Annual Pantheon Awards
Profluent today announced that it has been named the winner of the Emerging Innovator of the Year Award by California Life Sciences (CLS).
By Profluent · Via Business Wire · November 16, 2026
Profluent Partners With BioMarin to Design Novel Medicines Using AI
Profluent, the frontier AI lab for biology, today announced a collaboration with BioMarin Pharmaceutical Inc. to design and optimize novel enzyme therapies for BioMarin's pipeline. Under the agreement, Profluent will apply its foundational AI models to generate novel potential drug candidates, and BioMarin will screen the results with the goal to eventually advance the most promising designs.
By Profluent · Via Business Wire · September 30, 2026
Profluent Announces Strategic Partnership with Lilly to Develop AI-Designed Recombinases for Genetic Medicine
Profluent, the frontier AI company pioneering large-scale foundation models for protein design, today announced a multi-program strategic research collaboration with Eli Lilly and Company (“Lilly”) to develop and commercialize custom site-specific recombinases to address diseases with severe unmet needs.
By Profluent · Via Business Wire · April 28, 2026
Profluent Raises $106M to Scale Frontier AI Models for Programmable Biology
Profluent, a leader in frontier AI for protein design, today announced a $106 million financing co-led by Altimeter Capital and Bezos Expeditions, with participation from existing investors including Spark Capital, Insight Partners, and Air Street Capital. This round brings Profluent’s total funding to $150 million and will accelerate its mission to make biology programmable – transforming how therapeutics, diagnostics, agriculture, and biomanufacturing solutions are developed.
By Profluent · Via Business Wire · November 19, 2025
Profluent Announces Publication of Generative AI Research in Nature with New Results for OpenCRISPR-1
Profluent, the AI-first protein design company, today announced a publication in Nature describing the design of OpenCRISPR-1, the world’s first AI-created genome editor to successfully edit the human genome. These findings validate the use of Profluent’s large language models (LLMs) to generate custom gene editors that match or exceed the performance of naturally occurring CRISPR systems, with the potential to expand gene editing capabilities and accelerate therapeutic development.
By Profluent · Via Business Wire · July 30, 2025
Profluent Introduces ProGen3, Demonstrating Scaling Laws for Foundation Models in Writing Biology
Profluent, the AI-first protein design company, today unveiled ProGen3, a family of frontier protein models. Trained on the world’s largest, highly curated dataset of protein sequences, the company’s foundation model for protein generation enables writing new biology to solve challenges across biomedicine, agriculture, and industrial applications.
By Profluent · Via Business Wire · April 16, 2025
Profluent Demonstrates AI Can Engineer Protein-DNA Interactions Without Iterative Laboratory Screening
Profluent, the AI-first protein design company, today announced Protein2PAM, the first in a series of AI models that will broadly focus on protein-DNA interactions. Trained on large, bioinformatically curated databases of mined biological sequences, Protein2PAM demonstrates the power of Profluent’s language models to reprogram complex biological systems without the need for wet laboratory evolution or structural modeling.
By Profluent · Via Business Wire · January 7, 2025
Profluent Successfully Edits Human Genome with OpenCRISPR-1, the World’s First AI-Created and Open-Source Gene Editor
Profluent, the AI-first protein design company, today debuted the OpenCRISPRTM initiative, releasing the world’s first open-source, AI-generated gene editor. With this launch, Profluent demonstrates the first successful precision editing of the human genome with customizable gene editors designed from scratch with AI.
By Profluent · Via Business Wire · April 22, 2024
Profluent Secures $35M in Additional Funding and Key Industry Experts to Scale Foundational AI Models for Biomedicine and Tackle First Vertical in Gene Editing
Profluent, an AI-first protein design company, today announced the close of additional funding to bring the total raised to $44M. The $35M financing was led by Spark Capital, with participation from existing investors Insight Partners and Air Street Capital along with a syndicate of angel investors from OpenAI, Salesforce, Octant Bio, and Google including Jeff Dean, Chief Scientist of Google DeepMind. The company previously raised $9M from Insight Partners, Air Street Capital, AIX Ventures, and Convergent Ventures.
By Profluent · Via Business Wire · March 21, 2024


